Docetaxel rechallenge linked to longer survival than cabazitaxel, study suggests
A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or switch to cabazitaxel ...
Feb 18, 2026
0
5









